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Abstract 
Background and objective: Neoadjuvant chemotherapy (NAC) can be associated with anemia, which can lead to 
more perioperative blood transfusions (PBT). Usage of PBT is associated with worse oncological outcomes. We evalu-
ated the prevalence of preoperative anemia (PA) and the effect on hemoglobin levels depending on surgery timing 
after NAC.
Methods: A retrospective single-center study with 240 consecutive patients undergoing radical cystectomy (RC) 
between 2001 and 2014 for muscle-invasive urothelial carcinoma (MIBC). Anemia was defined according to the WHO 
classification (male ≤ 130 g/L, female ≤ 120 g/L). Multivariable logistical regression was used to identify factors associ-
ated with PA and Pearson correlation for evaluating the change in hemoglobin levels depending on surgery timing.
Results: Overall, 128 (53.3 %) patients were anemic pre-RC and 87 (36.3 %) patients received NAC. In a multivariable 
analysis, age, receipt of NAC, female gender, and low BMI were independent predictors of PA. In patients receiving 
NAC, the time to surgery from the last NAC cycle was correlated with the change in hemoglobin levels between the 
initiation of NAC and surgery.
Conclusions: PA was common in patients undergoing RC for MIBC. Receipt of NAC was found to be a strong predic-
tor of PA.
Clinical message: The emerging treatment of cisplatin based neoadjuvant chemotherapy for muscle-invasive blad-
der cancer, confers an increased risk for preoperative anemia. In the management of this malignancy, preoperative 
anemia renders further attention and focus.
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Background
Urothelial bladder cancer (UBC) is the fourth most 
common cancer in the Western World. The majority of 
patients diagnosed have non-invasive UBC, but around 
25  % are muscle-invasive (MIBC) at time of diagno-
sis (Burger et  al. 2013). The recommended treatment 
for patients with MIBC is radical cystectomy (RC) with 
lymph node dissection within 3 months to avoid progres-
sion and to decrease mortality. Addition of neoadjuvant 
chemotherapy (NAC) with cisplatin-based combina-
tions is recommended for patients fit for chemotherapy 
(Witjes et  al. 2015). This recommendation is based on 
the results of prospective randomized trials showing an 
absolute increase of survival with 5–8 %, 5 years median 
observation time (Sherif et  al. 2004; Vale 2005). RC is 
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considered major surgery and can be associated with 
significant blood loss and need for preoperative blood 
transfusions (PBT) (Shabsigh et  al. 2009). The use of 
PBT have been shown to have a negative effect on prog-
nosis in UBC (Abel et al. 2014; Linder et al. 2013; Gierth 
et  al. 2014; Morgan et  al. 2013). This detrimental effect 
has previously also been shown in other cancer types; 
gastric, colorectal and hepatocellular carcinoma (Ojima 
et al. 2009; Amato and Pescatori 2006; Wang et al. 2009). 
The mechanism of this unfavorable outcome is not fully 
understood. Negative immunomodulatory effects fol-
lowing transfusion have been suggested as one reason 
(Vamvakas and Blajchman 2007). Difficult surgical con-
ditions in more advanced tumors or in patients with a 
history of abdominal surgery or radiation therapy of the 
pelvic organs, may also be a reason for increased use of 
PBT. Thus adding confounding factors to the long term 
results following PBT. Preoperative anemia (PA) has 
also been suggested to be an independent predictor for 
the outcome following RC. A recent study showed that 
PA is associated with worse oncological outcomes in 
patients undergoing RC (Gierth et al. 2015). In order to 
improve treatment in urothelial MIBC, it is valuable to 
have patients optimized prior to RC. The use of NAC has 
postulated side effects such as anemia and this, in combi-
nation with a risk of significant blood loss during surgery, 
can increase the risk for PBT. We sought to evaluate the 
prevalence of PA, identify associated factors and evaluate 
the effect of NAC on hemoglobin (Hb) levels in patients 
with urothelial MIBC undergoing RC.
Methods
In this retrospective single-center study we analyzed all 
RCs due to MIBC from 2001 to 2014. From the database 
we identified 349 consecutive patients, undergoing RC 
at a tertiary referral center (Norrland university hospital 
in Umeå, Sweden). We excluded 34 patients with non-
urothelial cancer, 71 patients with non-invasive UBC and 4 
patients who underwent salvage cystectomy. In summary, 
240 consecutive patients constitute the study cohort. The 
study included 176 (73.3 %) male and 64 (26.7 %) female 
patients and the median age was 69  years (IQR 62–75). 
Clinicopathological variables were gathered from patient 
journals regarding age, gender, BMI (Body Mass Index), 
ASA (American Society of Anesthesiologists) score, 
comorbidities (previous heart attack, hypertonia, atrial 
fibrillation, asthma/Chronic obstructive pulmonary dis-
ease (COPD), Diabetes Mellitus), hydronephrosis, esti-
mated blood loss (EBL), receipt of PBT and number of 
units, receipt of NAC, clinical tumor stage (cT), Hb prior 
to first NAC-cycle, preoperative Hb and year of surgery.
Information about the change in Hb levels from the 
initiation of NAC until RC and also time to surgery from 
last NAC-cycle, was also evaluated. Hydronephrosis was 
defined as history of hydronephrosis prior to RC. PBT 
was defined as transfusion of allogenic red blood cells 
during the operation or in the postoperative hospitaliza-
tion. The decision to administer blood transfusion was 
made by treating physicians. No standardized thresholds 
for transfusion were in place during the study period.
Statistical analyses
Patients were categorized based on their Hb-level into 
two groups: Normal Hb-level or anemic. Anemia was 
defined as Hb ≤  130  g/L in male and Hb ≤  120  g/L in 
female patients, according to the WHO classification 
(Blanc et al. 1968). Clinical and pathologic characteristics 
were compared between the groups using Mann–Whit-
ney U test for continuous variables and Fisher’s exact test 
for categorical variables. Spearman’s rank correlation 
was used to check the development of EBL and usage of 
units of PBT over time. Univariable and multivariable 
logistic regression analysis was performed to identify fac-
tors associated with PA. In NAC-patients, Pearson cor-
relation was used to analyze the relationship between the 
change in Hb-levels following NAC and time to RC. The 
reported p values were two-sided and statistical signifi-
cance was set at 0.05. All statistical analyses were made 
using SPSS Statistics® 22 (SPSS, IBM Corp, Armonk, NY, 
USA).
Results
Association of preoperative anemia with clinicopathologic 
variables
The median Hb was 125.5  g/L (IQR 112.25–138.75). 
Overall, 128 (53.3  %) patients were anemic while 112 
(46.7 %) patients were non-anemic. Anemic patients had 
an older age (p = 0.004), higher ASA-score (p = 0.024), a 
higher incidence of hydronephrosis (p = 0.003), received 
NAC (p  <  0.001), lower EBL (p  =  0.035), more PBT 
(p = 0.003), and higher cT (p = 0.016), compared to non-
anemic patients. There was no significant difference in 
gender, BMI, history of heart attack, hypertonia, atrial 
fibrillation, asthma/COPD, Diabetes Mellitus or year of 
surgery (Table  1). Univariable analyses showed that age 
(Odds Ratio [OR] 1.046; p = 0.004), hydronephrosis (OR 
2.564; p = 0.003), receipt of NAC (OR 6.744; p < 0.001) 
and cT3 (OR 1.961; p =  0.041) or cT4 stage (OR 4.814; 
p = 0.048), both compared to cT2 were associated with 
PA. ASA III-IV, female gender, history of heart attack, 
hypertonia, atrial fibrillation, Asthma/COPD, Diabetes 
Mellitus or BMI were not statistically significant. Multi-
variable analyses adjusted for the effects of age, gender, 
BMI, ASA, hydronephrosis, receipt of NAC and cT. Age 
(OR 1.071; p  =  0.001) and receipt of NAC (OR 9.668; 
p < 0.001) remained independent predictors of PA in the 
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adjusted model, while hydronephrosis and cT did not. 
Female gender (OR 0.462; p = 0.046) and BMI (OR 0.908; 
p =  0.022) were found to be independent predictors in 
the adjusted model (Table 2). Further, there was no sig-
nificant difference in PA comparing complete responders 
(pT0N0M0) to non-responders or to progressing tumors 
(p = 0.778).
Development of NAC, anemia, PBT and EBL over time
The use of NAC increased during 2001–2014. The 
first patient receiving NAC was in 2003, with a steady 
increase during the years. In 2014, 81.3  % of patients 
with MIBC received NAC at this center (Fig. 1a). There 
was no statistically significant increase in the prevalence 
of PA over time (p = 0.067; Fig. 1b). Overall, the median 
EBL was 1000 ml (IQR 700–1712.5). There was no differ-
ence in EBL between patients receiving NAC compared 
to the non-NAC group (p  =  0.369). The median EBL 
decreased from 2500 (IQR 2000–11,500) ml in 2001 to 
875 (IQR 600–1050) ml in 2014 (p = 0.009). The median 
number of PBT was 4 units (IQR 2–6). No difference 
in the amount of PBT received was found between 
patients receiving NAC compared to the no-NAC group 
(p  =  0.441). The median number of units transfused 
perioperatively declined from 7 units (IQR 2–11) in 2001 
to 2.5 units (IQR 1–4) in 2014 (p = 0.003). Overall, 206 
patients (86.2 %) received a PBT during hospitalization 
for RC.
Table 1 Patient characteristics of the 240 patients with MIBC treated with radical cystectomy 2001–2014
Data are shown as median (IQR) or n (%)
BMI body mass index, ASA American Society of Anesthesiologists, COPD  chronic obstructive pulmonary disease, EBL estimated blood loss, PBT perioperative blood 
transfusion, cT clinical tumour stage
Parameter All patients (n = 240) Non-anemic (n = 112) Anemic (n = 128) p value
Age (years) 69 (62–75) 68 (61–73) 71 (65–76) 0.004
Sex 0.145
 Male 176 (73.3) 77 (68.8) 99 (77.3)
 Female 64 (26.7) 35 (31.2) 29 (22.7)
BMI 25.5 (22.8–28.4) 25.8 (23.8–28.8) 24.9 (22.5–27.8) 0.054
 Missing data 20 10 10
ASA score 0.024
 I 28 (11.8) 19 (17.3) 9 (7.1)
 II 120 (50.6) 57 (51.8) 63 (49.6)
 III 86 (36.3) 32 (29.1) 54 (42.5)
 IV 3 (1.3) 2 (1.8) 1 (0.8)
 Missing data 3 2 1
Prior heart attack 33 (13.8) 15 (13.4) 18 (14.1) 1
Hypertonia 104 (43.3) 51 (45.5) 53 (41.4) 0.602
Atrial fibrillation 19 (7.9) 8 (7.1) 11 (8.6) 0.812
Asthma/COPD 17 (7.1) 11 (9.8) 6 (4.7) 0.137
Diabetes mellitus 29 (12.1) 13 (11.6) 16 (12.5) 0.845
Hydronephrosis 63 (26.3) 19 (17) 44 (34.4) 0.003
Neoadjuvant chemotherapy 87 (36.3) 17 (15.2) 70 (54.7) <0.001
EBL (mL) 1000 (700–1712.5) 1200 (725–2000) 1000 (650–1475) 0.035
 Missing data 26 15 11
Units of PBT 4 (2–6) 2 (1–6) 4 (2–6) 0.003
cT 0.017
 cT2 178 (72.2) 92 (82.1) 86 (67.2)
 cT3 51 (21.3) 18 (16.1) 33 (25.8)
 cT4 11 (4.6) 2 (1.8) 9 (7.0)
Year of surgery 0.469
 2001–2002 20 (8.3) 12 (10.7) 8 (6.3)
 2003–2005 43 (17.9) 21 (18.8) 22 (17.2)
 2006–2008 55 (22.9) 27 (24.1) 28 (21.9)
 2009–2011 73 (30.4) 34 (30.4) 39 (30.5)
 2012–2014 49 (20.4) 18 (16.1) 31 (24.2)
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Effects of neoadjuvant chemotherapy on hemoglobin 
levels
Table  3 shows the details of NAC treatment. In NAC-
patients (n =  87), the median time to surgery from the 
last cycle of NAC was 35 days (IQR 29–42). The median 
change in Hb-level was -15 g/L (IQR −26 to −3.5). The 
change in Hb-levels can also be expressed in that the 
number of patients with anemia prior to NAC was 48 
(55.2 %), compared to 70 (80.5 %) who had anemia prior 
to RC post-NAC. The change in Hb following NAC was 
correlated with time to RC (Pearson correlation coeffi-
cient: 0.221, p value: 0.042, Fig. 2a). There was an upward 
trend towards an increasing Hb after 7 weeks (Fig. 2b).
Discussion
The increased risk of adverse outcomes following PBT in 
conjunction with RC for MIBC, needs to be addressed. 
Utilization of PBT affects the long term results, not only 
pertaining to overall and cancer-specific mortality but 
also to the long term risk of tumor recurrence (7). In gen-
eral, PA increases the risk for usage of PBT, and we found 
it of importance to investigate effects of NAC on PA. This 
with background of optimizing this rapidly emerging 
treatment, which ultimately aims to improve both over-
all and cancer-specific mortality. We found that 53.3  % 
of all the patients had PA. This is a higher prevalence 
than found in other studies, having reported rates rang-
ing from 39.3 to 51.5  % (Gierth et  al. 2014, 2015; Mos-
chini et  al. 2015). However, two of the studies excluded 
patients receiving NAC and in the third study only 2.9 % 
received NAC. We identified four independent predictors 
of PA: Age, gender, receipt of NAC and BMI. Receipt of 
NAC was the strongest predictor (OR 9.668). Anemia has 
previously been shown to be more common with increas-
ing age (Gierth et  al. 2015). A lower BMI could reflect 
the patient´s state of health, which in turn can have an 
effect on Hb-levels. The fact that females had a lower 
risk of PA could partly be explained by a lower anemia 
threshold in the WHO-definition. Our current praxis is 
that RC is planned 4  weeks after final NAC-cycle. The 
planned time to RC in other centers in Sweden varies; 
some centers proceed after 6–8 weeks. The current EAU-
recommendation regarding timing of RC is that the oper-
ation is not to be delayed more than 3 months. However, 
this recommendation is based on single-center studies 
on chemo naïve patients. A recent study explored the 
effect of delaying RC > 3 months on survival in a nation-
wide cohort (Bruins et  al. 2016). The investigators also 
included NAC-patients, showing that the overall survival 
was similar between patients undergoing RC < 3 months 
compared to patients with RC > 3 months. This suggests 
that the 3-month recommendation may not be applicable 
Table 2 Univariable and multivariable logistic regression analysis of risk factors associated with preoperative anemia
OR odds ratio, CI confidence interval, BMI body mass index, ASA American Society of Anesthesiologists, NAC neoadjuvant chemotherapy, COPD chronic obstructive 
pulmonary disease, cT  clinical tumor stage
Variable Univariate Multivariate
OR 95 % CI p value OR 95 % CI p value
Age 1.046 1.015–1.078 0.004 1.071 1.029–1.114 0.001
Gender
 Male Referent Referent
 Female 0.644 0.363–1.146 0.134 0.462 0.216–0.985 0.046
BMI 0.944 0.884–1.007 0.081 0.908 0.837–0.986 0.022
ASA score
 I and II Referent Referent
 III and IV 1.708 1.000–2.917 0.050 1.761 0.886–3.500 0.106
Hydronephrosis 2.564 1.388–4.736 0.003 1.761 0.829–3.778 0.140
Reciept of NAC 6.744 3.619–12.569 <0.001 9.668 4.456–20.480 <0.001
Prior heart attack 1.058 0.506–2.213 0.881
Hypertonia 0.845 0.507–1.410 0.521
Atrial fibrillation 1.222 0.474–3.155 0.678
Asthma/COPD 0.452 0.151–1.264 0.130
Diabetes mellitus 1.088 0.499–2.374 0.832
cT
 cT2 Referent Referent
 cT3 1.961 1.029–3.739 0.041 1.781 0.767–4.135 0.179
 cT4 4.814 1.011–22.912 0.048 2.878 0.506–16.378 0.233
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for NAC-patients. On the other hand, in NAC-non-
responders, an increased delay to RC might have a nega-
tive effect on survival. The problem with non-responders 
is currently being handled differently, depending on local 
traditions. Computerized tomography is commonly used 
in this center after the second NAC-cycle, for identify-
ing non-responders and in case of non-response or pro-
gress, we proceed directly to RC avoiding NAC-cycle 3. 
Another suggested method is cystoscopy, with a recent 
study showing that cystoscopy-findings after NAC-cycle 
2 are independent predictors of extravesical disease and 
pathologic downstaging (Mansour et  al. 2015). In our 
study we have seen that utilization of NAC has increased 
in the last decade. Thus one can assume that with more 
patients receiving NAC, PA could become more preva-
lent. Another interesting approach would be to evalu-
ate differences in PA, comparing complete responders 
to non-responders, thus postulating that micrometastic 
disease in the latter subgroup might be reflected in PA. 
Yet in this limited material there was no difference. Fur-
ther we did not observe any differences in EBL or the 
amount of PBT received in the NAC group compared to 
the no-NAC-group. One reason might be that the NAC-
patients in our material were significantly younger than 
the chemo naïve patients (p  =  0.049). The amount of 
PBT decreased totally during the studied period. This is 
probably due to fewer surgeons performing RC following 
an ongoing national centralization of RC, an increased 
awareness of both perioperative bleeding and EBL due to 
national registers (The Swedish bladder cancer register 
with increasing national coverage from the 2000s and the 
Swedish cystectomy register which started in 2011) and 
further the rapidly increasing use of ileal conduit (86.5 % 
for 2013 in Sweden) instead of other more time consum-
ing urinary diversions.
Within the scope of prospective trials addressing these 
matters, consideration could be given to identify and 
treat anemia prior to RC, specifically without allogenic 
blood transfusions. Another way to address the described 
problem could be in adjusting the time to surgery after 
NAC, in order to let the Hb-level recover, and thus 
reduce the amount of patients with PA and the number 
of PBT required. In a few patients (n =  12) waiting for 





































Fig. 1 a Use of neoadjuvant chemotherapy, 2001–2014. b Prevalence of preoperative anemia, 2001–2014. p = 0.067
Table 3 Information about  given NAC and  hemoglobin 
values in the 87 patients who received NAC
Data are shown as median (IQR) or n (%)
Variable Total (n = 87)
NAC treatment
 MVAC 53 (60.9)
 HD-MVAC 21 (24.1)
 Cisplatin-Gemzar 6 (6.9)
 MVEC 5 (5.7)
 Carboplatin-Gemzar 1 (1.1)
 MVAC + Taxotere 1 (1.1)
Hemoglobin level (g/L)
 Prior to NAC 127 (117–127)
 Prior to surgery 115 (107–123)
 Anemic prior to NAC 48 (55.2)
 Anemic prior to surgery 70 (80.5)
 Number of days from last NAC to surgery 35 (29–42)
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was a trend towards a smaller Hb-decrease post-NAC, 
compared with patients having a shorter interval to RC 
having a larger decrease. More data is needed to con-
clusively say if an increased time to surgery could affect 
the change in Hb-levels. More studies are also required 
to assess if delayed surgery following NAC has an impact 
on survival. The limitations of this study include its retro-
spective design on a relatively small study population. No 
pathological review was made, and due to the long study 
period multiple surgeons were involved. Furthermore no 
data on GFR were available which could add additional 
information regarding selection of patients to NAC and 
the individual effect of NAC on renal function. More data 
from centers where the planned time to RC after NAC is 
longer could also add value to the analysis of the impact 
of delayed surgery on PA and the amount of PBT.
Conclusions
PA was common in patients undergoing RC for MIBC. 
Receipt of NAC was found to be a strong predictor of PA. 
This has not been described previously in any evaluations 
pertaining to NAC-treatment of urothelial MIBC. Strate-
gies to identify and manage patients with PA should be 
developed to avoid PBT in order to optimize manage-
ment and prognosis, yet both larger retrospective and 
also prospective evaluations relating to PA and NAC, 
need first to be undertaken.
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